Donor-specific antibodies require preactivated immune system to harm renal transplant

[1]  M. Zeier,et al.  Pre‐transplant soluble CD30 in combination with total DSA but not pre‐transplant C1q‐DSA predicts antibody‐mediated graft loss in presensitized high‐risk kidney transplant recipients , 2016, HLA.

[2]  T. Fehr,et al.  Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing , 2015, Transplantation.

[3]  A. Sinha,et al.  Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization , 2015, Transplantation.

[4]  X. Jouven,et al.  Complement-binding anti-HLA antibodies and kidney-allograft survival. , 2013, The New England journal of medicine.

[5]  Sonia Y. Velásquez,et al.  Release of Soluble CD30 After Allogeneic Stimulation Is Mediated by Memory T Cells and Regulated by IFN-&ggr; and IL-2 , 2013, Transplantation.

[6]  A. Gaber,et al.  Outcomes of living donor renal transplants with a negative cross-match and pretransplant donor-specific antibody. , 2013, Transplantation proceedings.

[7]  A. Webster,et al.  Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation , 2013, Transplantation.

[8]  Sonia Y. Velásquez,et al.  Alloantigen-stimulated induction and release of CD30 in patients with end-stage renal failure. , 2012, Human immunology.

[9]  M. Verhaar,et al.  Pretransplant Donor‐Specific HLA Class‐I and ‐II Antibodies Are Associated With an Increased Risk for Kidney Graft Failure , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  D. Tyan,et al.  Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. , 2011, Human immunology.

[11]  G. Opelz,et al.  No Association of Kidney Graft Loss With Human Leukocyte Antigen Antibodies Detected Exclusively by Sensitive Luminex Single-Antigen Testing: A Collaborative Transplant Study Report , 2011, Transplantation.

[12]  J. McCluskey,et al.  Tissue Specificity of Cross-Reactive Allogeneic Responses by EBV EBNA3A-Specific Memory T Cells , 2011, Transplantation.

[13]  S. Busque,et al.  C1q-Fixing Human Leukocyte Antigen Antibodies Are Specific for Predicting Transplant Glomerulopathy and Late Graft Failure After Kidney Transplantation , 2011, Transplantation.

[14]  M. Zeier,et al.  An Integrative Approach for the Transplantation of High-Risk Sensitized Patients , 2010, Transplantation.

[15]  G. Opelz,et al.  Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report. , 2009, Human immunology.

[16]  Junchao Cai,et al.  Intact HLA Not &bgr;2m-free Heavy Chain-Specific HLA Class I Antibodies Are Predictive of Graft Failure , 2009, Transplantation.

[17]  G. Russ,et al.  Anti‐HLA Donor‐Specific Antibodies Detected in Positive B‐Cell Crossmatches by Luminex® Predict Late Graft Loss , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  W. Chapman,et al.  Activated Effector and Memory T Cells Contribute to Circulating sCD30: Potential Marker for Islet Allograft Rejection , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  M. Christiaans,et al.  Clinical Relevance of Pretransplant Donor-Directed Antibodies Detected by Single Antigen Beads in Highly Sensitized Renal Transplant Patients , 2008, Transplantation.

[20]  F. Heinemann,et al.  Association of Elevated Pretransplant sCD30 Levels With Graft Loss in 206 Patients Treated With Modern Immunosuppressive Therapies After Renal Transplantation , 2007, Transplantation.

[21]  W. Padberg,et al.  Post‐Transplant sCD30 and Neopterin as Predictors of Chronic Allograft Nephropathy: Impact of Different Immunosuppressive Regimens , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  G. Opelz,et al.  Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30. , 2003, Transplantation.

[23]  M. Tarkowski.  Expression and a role of CD30 in regulation of T-cell activity , 2003, Current opinion in hematology.

[24]  O. Martinez,et al.  CD30 Expression Identifies the Predominant Proliferating T Lymphocyte Population in Human Alloimmune Responses1 , 2002, The Journal of Immunology.

[25]  G. Opelz,et al.  Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. , 2002, Journal of the American Society of Nephrology : JASN.

[26]  G. Opelz,et al.  Kidney graft failure and presensitization against HLA Class I and Class II antigens1 , 2002, Transplantation.

[27]  A. Al-Shamkhani,et al.  Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30 , 2002, European journal of immunology.

[28]  N. Greenspan,et al.  Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. , 1999, Journal of immunology.

[29]  G. May,et al.  HLA class I and class II antibodies: monitoring before and after kidney transplantation and their clinical relevance. , 1998, Transplantation.

[30]  P. Terasaki,et al.  Significance of the positive crossmatch test in kidney transplantation. , 1969, The New England journal of medicine.